title: Nasal septum perforation in a breast cancer patient treated with bevacizumab.
authors.forename: A Pinto
authors.initials: AP
authors.lastname: Marín
authors.forename: A Redondo
authors.initials: AR
authors.lastname: Sánchez
authors.forename: E Espinosa
authors.initials: EE
authors.lastname: Arranz
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008408:Mastectomy; D009300:Nasal Septum / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009367:Neoplasm Staging; D009668:Nose Diseases / Q000139:chemically induced*; D011878:Radiotherapy
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab